• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Osteoarthritis and cartilage open

    Osteoarthritis and cartilage open

    JournalISSN 2665-9131eISSN 2665-9131

    年发文量

    研究主题

    论文(724)

    排序
    1Sarcopenic Obesity is Strongly Associated with Incidence, Progression, and Worsening of Knee Osteoarthritis: the Johnston County Osteoarthritis Project
    David M. Werner,Carolina Alvarez,John A. Batsis,Reece Blay, Laura D. Bilek,Amanda E. Nelson,Yvonne M. Golightly
    2026
    引用
    AI阅读
    加入学术空间
    2Single-cell RNA Sequencing Elucidates the Divergent Response of Human Osteoarthritic Chondrocyte Subsets to Transforming Growth Factor Beta 1
    Judith Veldman,Mauricio N. Ferrao Blanco,Peter van der Kraan,Nicole Kops, Wendy JLM Koevoet,Eric M.J. Bindels, Gregory van Beek,Andrea Lolli,Eric Farrell, Gerjo JVM van Osch
    2026
    引用
    AI阅读
    加入学术空间
    3Effects of MRI-based Eligibility Criteria on Clinical Trial Recruitment and Sensitivity to Cartilage Thickness Change in Advanced Knee Osteoarthritis
    Felix Eckstein,Frank W. Roemer,David J. Hunter,Jamie E. Collins,Philip G. Conaghan,Ali Guermazi,Wolfgang Wirth

    Objective To determine how MRI-based exclusion of selected structural pathologies and cartilage damage thresholds affect recruitment and responsiveness of cartilage thickness decline in a clinical trial cohort with advanced radiographic knee osteoarthritis. Method This post-hoc analysis included the 200 placebo-arm participants of the ROCCELLA trial, all with medial joint space narrowing OARSI grade 1 or 2. Rapid OsteoArthritis MRI Eligibility Score (ROAMES)-type exclusions were applied; MOAKS was mapped to corresponding WORMS cartilage scores to facilitate interpretation. 12-month central medial femorotibial cartilage thickness change was analyzed by expert segmentation; responsiveness was expressed as standardized response mean (SRM). Results Thirty-six of 200 participants (18%) had an exclusionary finding according to ROAMES criteria, including 28 meniscal root tears. Among 188 participants with 12-month MRI, the mean cartilage loss was −113 μm (SRM -0.43); it was −131 μm (SRM -0.41) with and −109 μm (SRM -0.44) in the absence of exclusionary findings. Among 154 knees without exclusionary findings but with MRI, 91 had medial femorotibial WORMS≥5. These showed a −133 μm loss (SRM -0.50), compared with −74 μm (SRM -0.35) in 63 WORMS<5 knees. Excluding WORMS≥5 anywhere in the knee left 46 knees, with −86 μm loss (SRM −0.38); 10 knees with WORMS = 6 showed −154 μm loss (SRM -0.77). Conclusion MRI screening identified ROAMES-type pathologies in a substantial proportion of radiographically eligible participants and their exclusion minimally affected cartilage thickness responsiveness. Excluding advanced cartilage damage, however, substantially reduced amounts and sensitivity to cartilage thickness decline. Recruitment, measurement performance, and treatment-response assumptions must be considered when defining MRI eligibility criteria.

    2026
    引用
    AI阅读
    加入学术空间
    4Excess Healthcare Use Attributable to Depression and Anxiety in Osteoarthritis: A Matched Register-Based Cohort Study
    Ali Kiadaliri, Andrea Dell’Isolla,Karin Magnusson,Clara Hellberg,Martin Englund

    Objective To quantify excess healthcare use attributable to incident depression and anxiety in people with osteoarthritis (OA). Methods A matched register-based cohort study. Individuals aged 40+ residing in Skåne in 2009 with an OA diagnosis during 1998–2009 and a first diagnosis or medication dispensation for depression (n = 8125) or anxiety (n = 9545) during 2010–2018 were defined as cases. These were matched to up to 4 controls by birth year, sex and follow-up time. We measured healthcare consultations (HCCs) and defined daily dose (DDD) of all medications at 3-month intervals and hospital inpatient days at 1-year intervals from 3 years before to 3 years after the index date (depression/anxiety diagnosis date). We used two-part models to estimate excess healthcare use attributable to depression/anxiety. Results Persons with depression/anxiety had higher healthcare uses than their matched controls throughout the observation period. The greatest differences were observed in the quarter after diagnosis for HCCs and medication, and the year before diagnosis for inpatient days. Over 6-year observation period, persons with depression/anxiety had, on average, 46 (95% CI: 45, 48)/46 (44, 47) more HCCs, 3306 (3 112, 3501)/2768 (2 590, 2946) more DDD of medications, and 13 (12, 14)/14 (13, 15) more inpatient days than their matched controls. Conclusion Among OA patients, those with depression/anxiety had more healthcare use from three years before to three years after diagnosis than controls, suggesting possible delay in the diagnosis and management of depression/anxiety and the need for improved care.

    2026
    引用
    AI阅读
    加入学术空间
    5Low-dose Radiotherapy in Patients with Osteoarthritis: A Multidisciplinary Roadmap from Biological Rationale to Definitive Evaluation
    Gilles Colin, Jean-François Kaux,Patrick Durez, François Lallemand,Pierre Blanchard,Clio Ribbens,Olivier Malaise,Jérémie Sellam

    Objective To critically reassess low-dose radiotherapy (LDRT) in patients with osteoarthritis (OA) across the full translational pathway, from biological rationale to clinical efficacy and the requirements for definitive evaluation. Methods This multidisciplinary narrative review appraised mechanistic, preclinical and clinical evidence for LDRT in OA, with particular emphasis on the translational relevance of experimental models and on randomized evidence, especially sham-controlled trials. Recent technical consensus, safety assessments and OA trial-methodology literature were also considered. Results Preclinical studies support context-dependent immunomodulatory effects of LDRT involving endothelial–leukocyte interactions, immune-cell activation and joint-tissue crosstalk, but much of this evidence derives from reductionist or inflammatory models rather than chronic human OA. OA-specific experimental evidence remains limited. Clinically, two sham-controlled trials using 6 × 1 Gy were negative, whereas more recent studies using 6 × 0.5 Gy have reported positive signals that remain preliminary or methodologically limited. No responder phenotype has been validated. A definitive evaluation should therefore integrate clinically meaningful pain and/or functional impairment despite optimized standard OA care, prospective evaluation of inflammatory or imaging-based enrichment, biological target-engagement measures, standardized radiation delivery, rigorous sham-controlled OA outcomes, long-term safety, and assessment of clinical and health-system feasibility. Conclusion There is a biological rationale for LDRT in OA, but current evidence remains insufficient to support routine use in patients with OA. Its future role should be defined through adequately powered, phenotype-informed sham-controlled trials conducted jointly by OA and radiation experts.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 724 篇论文

    高被引作者

    作者引用发文
    Christian Barton17413
    Kemp Joanne L1736
    Flavia Cicuttini15611
    Wallis Jason1414
    Ewa M Roos1418
    Jos Runhaar13420
    Ali Mobasheri13211
    Tuhina Neogi13019
    Yuanyuan Wang1258
    Mahnuma Estee1185

    高产作者

    作者引用发文
    Martin Englund10426
    Elena Losina9522
    Collins Jamie E6321
    Jos Runhaar13420
    Tuhina Neogi13019
    David Hunter6718
    Haugen Ida K7617
    Yvonne Golightly5715
    Aleksandra Turkiewicz5215
    Jeffrey N. Katz7514

    相关期刊

    Tsitologiia
    Revista de la Facultad de Farmacia, Universidad Central de Venezuela
    Theoretical biology & medical modelling
    Current protocols in toxicology
    Journal of HIV and AIDS
    Reactive oxygen species (Apex, N.C.)
    Itch (Philadelphia, Pa.)
    Open journal of bioresources
    Research Journal of Seed Science
    Endocrine Metabolic & Immune Disorders-Drug Targets